GRI Bio Inc. (GRI) - Net Assets
Based on the latest financial reports, GRI Bio Inc. (GRI) has net assets worth $6.01 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.67 Million) and total liabilities ($2.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GRI Bio Inc. (GRI) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.01 Million |
| % of Total Assets | 69.33% |
| Annual Growth Rate | 68.94% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 911.8 |
GRI Bio Inc. - Net Assets Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore GRI total asset value for the complete picture of this company's asset base.
Annual Net Assets for GRI Bio Inc. (2018–2025)
The table below shows the annual net assets of GRI Bio Inc. from 2018 to 2025. For live valuation and market cap data, see GRI market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.01 Million | +49.01% |
| 2024-12-31 | $4.03 Million | +1456.76% |
| 2023-12-31 | $259.00K | +115.94% |
| 2022-12-31 | $-1.62 Million | +65.60% |
| 2021-12-31 | $-4.72 Million | -224.90% |
| 2020-12-31 | $-1.45 Million | -145.24% |
| 2019-12-31 | $3.21 Million | +2001.36% |
| 2018-12-31 | $152.94K | -- |
Equity Component Analysis
This analysis shows how different components contribute to GRI Bio Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4738335400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $57.70 Million | 960.45% |
| Total Equity | $6.01 Million | 100.00% |
GRI Bio Inc. Competitors by Market Cap
The table below lists competitors of GRI Bio Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vicarious Surgical Inc.
NYSE:RBOT
|
$3.15 Million |
|
Forza X1 Inc
NASDAQ:FRZA
|
$3.15 Million |
|
Haffner Energy SA
PA:ALHAF
|
$3.15 Million |
|
Svenska Aerogel Holding AB (publ)
ST:AERO
|
$3.15 Million |
|
Softimat S.A.
BR:SOFT
|
$3.15 Million |
|
Pembroke VCT PLC
LSE:PEMB
|
$3.14 Million |
|
CubicFarm Systems Corp
V:CUB
|
$3.14 Million |
|
Noratis AG
XETRA:NUVA
|
$3.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GRI Bio Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,032,000 to 6,008,000, a change of 1,976,000 (49.0%).
- Net loss of 11,956,000 reduced equity.
- Share repurchases of 1,000 reduced equity.
- New share issuances of 15,560,000 increased equity.
- Other factors decreased equity by 1,627,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.96 Million | -199.0% |
| Share Repurchases | $1.00K | -0.02% |
| Share Issuances | $15.56 Million | +258.99% |
| Other Changes | $-1.63 Million | -27.08% |
| Total Change | $- | 49.01% |
Book Value vs Market Value Analysis
This analysis compares GRI Bio Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $171.65 | $2.18 | x |
| 2019-12-31 | $3606.96 | $2.18 | x |
| 2020-12-31 | $-1631.87 | $2.18 | x |
| 2021-12-31 | $-407.17 | $2.18 | x |
| 2022-12-31 | $-1400.86 | $2.18 | x |
| 2023-12-31 | $164.13 | $2.18 | x |
| 2024-12-31 | $615.95 | $2.18 | x |
| 2025-12-31 | $61.20 | $2.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GRI Bio Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -199.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.44x
- Recent ROE (-199.00%) is above the historical average (-1045.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -2819.85% | 0.00% | 0.00x | 4.18x | $-4.33 Million |
| 2019 | -107.80% | 0.00% | 0.00x | 1.33x | $-3.79 Million |
| 2020 | 0.00% | -2531.00% | 0.10x | 0.00x | $-2.39 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.83 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.05 Million |
| 2023 | -5033.59% | -59.89% | 7.36x | 11.41x | $-13.06 Million |
| 2024 | -203.55% | -36.41% | 3.93x | 1.42x | $-8.61 Million |
| 2025 | -199.00% | 0.00% | 0.00x | 1.44x | $-12.56 Million |
Industry Comparison
This section compares GRI Bio Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GRI Bio Inc. (GRI) | $6.01 Million | -2819.85% | 0.44x | $3.15 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more